Immune checkpoint inhibitors have reshaped modern cancer treatment by releasing the brakes on anti-tumor immunity, yet a new review argues that the African communities who could benefit most from these drugs remain the least likely to receive them. The review, published in AIDS Research and Therapy, examines why people living with HIV were systematically excluded from the pivotal registration trials that established checkpoint blockade as a cornerstone of oncology, and why that exclusion carries particular weight in sub-Saharan Africa.
The stakes are geographic as much as scientific. Sub-Saharan Africa bears 67 percent of the global HIV burden while simultaneously facing what the authors describe as an escalating and complex cancer epidemic. That combination means the region concentrates precisely the patient population for whom questions about immunotherapy safety and effectiveness in HIV remain most consequential, even as it lacks the trial infrastructure needed to answer those questions locally.
The mechanistic rationale for using checkpoint inhibitors in HIV is rooted in T-cell exhaustion. Chronic HIV infection progressively exhausts HIV-specific T cells through sustained upregulation of inhibitory receptors, including PD-1, TIGIT, LAG-3, and TIM-3. Because checkpoint blockade is designed to disengage these very inhibitory pathways, the review notes that this profound exhaustion provides a strong theoretical case for using the drugs to restore immune function and clear infected cells, not only to treat cancer.
On the clinical evidence side, the review synthesizes recent peer-reviewed publications, clinical trial registries, and regional health assessments. Its central conclusion is that immune checkpoint inhibitors can be safely and effectively administered to virologically suppressed people living with HIV who have adequate CD4+ cell counts. In this group, cancer response rates have been comparable to those observed in HIV-negative cohorts.
Two cancer types illustrate the point in detail. In PD-1 inhibitor-naïve Kaposi sarcoma, objective response rates exceeding 80 percent have been reported among treated patients. Similarly encouraging safety and response data have emerged in HIV-positive patients with lung cancer, where PD-1 inhibitors produce outcomes that the review characterizes as broadly comparable to those in HIV-negative populations.
Yet the immunological landscape in Africa is not simply a transplant of findings from European, American, or Asian trials. Endemic co-infections across the region promote an immunosuppressive, Th2-biased immune environment. According to the review, this milieu may alter checkpoint receptor expression, modify how patients respond to checkpoint inhibitors, and shift toxicity profiles, meaning that response and safety data gathered elsewhere cannot be assumed to apply unchanged.
The most alarming gap the authors identify is structural: sub-Saharan Africa remains almost entirely excluded from immune checkpoint inhibitor clinical trials. They attribute this exclusion to acute shortages of oncology and research workforce, gaps in trial infrastructure, and the prohibitive costs of running registration-grade studies in the region. The result is a feedback loop in which the population with the greatest theoretical need generates the least trial evidence.
The review frames extending immunotherapy benefits to this population as an ethical imperative rather than an optional extension of global oncology. Its proposed path forward is pragmatic rather than purely aspirational: African-led trial designs suited to local health systems, routine helminth screening to account for co-infection effects, sustainable capacity-building so that research infrastructure endures beyond individual studies, and equitable global partnerships that share both the costs and the scientific returns of immunotherapy research.
The unfinished work, the authors argue, is to test and deliver that evidence where two epidemics overlap, rather than continuing to infer African outcomes from trials conducted almost entirely elsewhere.
Subject of Research: Immune checkpoint inhibitor therapy for people living with HIV in sub-Saharan Africa
Article Title: Immune checkpoint inhibitors for African people living with HIV: T-cell exhaustion, endemic co-infections, and the oncology trial gap
Article References: Das, A., ElShabrawi, M., Keswani, K., Muzaffer, R., Nandan, C., Alupei, E., Faiz, D., & Alamy, H. (2026). Immune checkpoint inhibitors for African people living with HIV: T-cell exhaustion, endemic co-infections, and the oncology trial gap. AIDS Research and Therapy. https://doi.org/10.1186/s12981-026-00961-7
Image Credits: AI Generated
DOI: 10.1186/s12981-026-00961-7
Keywords: immune checkpoint inhibitors, HIV, sub-Saharan Africa, T-cell exhaustion, PD-1, Kaposi sarcoma, lung cancer, endemic co-infections, clinical trials, health equity, oncology, AIDS Research and Therapy
News Source: Nathaniel Bowman. (October 29, 2026). Checkpoint Inhibitors Show Promise for People With HIV, but Africa Remains Excluded. Scienmag.
